Movatterモバイル変換

ATC code C

From Wikipedia, the free encyclopedia

Pharmaceutical drug classification

ATC code C:Cardiovascular system
C01Cardiac therapy C02Antihypertensives C03Diuretics C04Peripheral vasodilators C05Vasoprotectives C07Beta blocking agents C08Calcium channel blockers C09 Agents acting on therenin–angiotensin system C10Lipid modifying agents
Other ATC codes
A B C D G H QI J L M N P R S V

ATC code CCardiovascular system is a section of theAnatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by theWorld Health Organization (WHO) for the classification ofdrugs and other medical products.^[1]^[2]^[3]^[4]

Codes forveterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example,QC.^[5]
National versions of the ATC classification may include additional codes not present in this list, which follows the WHO version.

References

[edit]

^"ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis".National Institutes of Health. Retrieved1 February 2020.
^"Anatomical Therapeutic Chemical (ATC) Classification".World Health Organization. Retrieved3 January 2022.
^"Structure and principles".WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved3 January 2022.
^"ATC/DDD Index 2022: code C".WHO Collaborating Centre for Drug Statistics Methodology.
^"ATCvet Index 2022: code QC".WHO Collaborating Centre for Drug Statistics Methodology.

v t e Major chemical drug groups – based upon theAnatomical Therapeutic Chemical Classification System
gastrointestinal tract /metabolism (A)	stomach acid Antacids H₂ antagonists Proton-pump inhibitors Antiemetics Laxatives Antidiarrhoeals /Antipropulsives Anti-obesity drugs Diabetes medication Vitamins Dietary minerals
blood and blood forming organs (B)	Antithrombotics Antiplatelets Anticoagulants Thrombolytics / fibrinolytics Antihemorrhagics Platelets Coagulants Antifibrinolytics
cardiovascular system (C)	cardiac therapy /antianginals Cardiac glycosides Antiarrhythmics Cardiac stimulants Antihypertensives Diuretics Vasodilators Beta blockers Calcium channel blockers renin–angiotensin system ACE inhibitors Angiotensin II receptor antagonists Renin inhibitors Antihyperlipidemics Statins Fibrates Bile acid sequestrants
skin (D)	Emollients Cicatrizants Antipruritics Antipsoriatics Medicated dressings
genitourinary system (G)	Hormonal contraception Fertility agents Selective estrogen receptor modulators Sex hormones
endocrine system (H)	Hypothalamic–pituitary hormones Corticosteroids Glucocorticoids Mineralocorticoids Sex hormones Thyroid hormones /Antithyroid agents
infections and infestations (J,P,QI)	Antimicrobials:Antibacterials (Antimycobacterials) Antifungals Antivirals Antiparasitics Antiprotozoals Anthelmintics Ectoparasiticides Intravenous immunoglobulin Vaccines
malignant disease (L01–L02)	Anticancer agents Antimetabolites Alkylating Spindle poisons Antineoplastic Topoisomerase inhibitors
immune disease (L03–L04)	Immunomodulators Immunostimulants Immunosuppressants
muscles,bones, andjoints (M)	Anabolic steroids Anti-inflammatories Non-steroidal anti-inflammatory drugs Antirheumatics Corticosteroids Muscle relaxants Bisphosphonates
brain and nervous system (N)	Analgesics Anesthetics General Local Anorectics Anti-ADHD agents Antiaddictives Anticonvulsants Antidementia agents Antidepressants Antimigraine agents Antiparkinson agents Antipsychotics Anxiolytics Aphrodisiacs Depressants Entactogens Entheogens Euphoriants Hallucinogens Psychedelics Dissociatives Deliriants Hypnotics /Sedatives Mood stabilizers Motivation-enhancing drug Neuroprotectives Nootropics Neurotoxins Orexigenics Serenics Stimulants Wakefulness-promoting agents
respiratory system (R)	Decongestants Bronchodilators Cough medicines H₁ antagonists
sensory organs (S)	Ophthalmologicals Otologicals
otherATC (V)	Antidotes Contrast media Radiopharmaceuticals Dressings Senotherapeutics
Drugs Pharmacological classification systems ATC codes Medicine portal

Cardiac glycosides (C01A)

Bufadienolides

Bufo	Arenobufagin Bufotalin Cinobufagin Marinobufagin
Scilla	Proscillaridin Scilliroside
Kalanchoe	Daigremontianin

Cardenolides

Digitalis	Acetyldigitoxin Acetyldigoxin Digitoxin^# Digoxin^# Lanatoside C Deslanoside Metildigoxin Gitoformate
Strophanthus	Ouabain (g-Strophanthin) k-Strophanthin Cymarin
Thevetia	Peruvoside

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Antiarrhythmic agents (C01B)

Channel blockers

class I
(Na⁺ channel blockers)

class Ia (Phase 0→ andPhase 3→)	Ajmaline Disopyramide Hydroquinidine Lorajmine Prajmaline Procainamide^# Quinidine^# Sparteine
class Ib (Phase 3←)	IV Lidocaine^# enteral Aprindine Mexiletine Tocainide
class Ic (Phase 0→)	Encainide^‡ Ethacizine Flecainide Indecainide^‡ Lorcainide Moracizine^‡ Propafenone

class III
(Phase 3→,K⁺ channel blockers)

class IV
(Phase 4→,Ca²⁺ channel blockers)

Receptor agonists
andantagonists

class II (Phase 4→,β blockers)	Nadolol Pindolol Propranolol cardioselective Acebutolol Atenolol Esmolol Landiolol Metoprolol
A₁ agonist	Adenosine Benzodiazepines Barbiturates
M₂	muscarinic antagonist:Atropine Disopyramide Quinidine muscarinic agonist:Digoxin
α receptors	Amiodarone Bretylium Quinidine Verapamil

Ion transporters

Na⁺/ K⁺-ATPase	Digitoxin Digoxin Ouabain

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Cardiac stimulants excluding cardiac glycosides (C01C)

Adrenergic and
dopaminergic agents

Adrenergic agonists

α	Denopamine Metaraminol Methoxamine Midodrine Norfenefrine Oxedrine Phenylephrine
β	Arbutamine Dobutamine Isoprenaline Prenalterol
mixed	Amezinium metilsulfate Droxidopa Epinephrine # Etilefrine Norepinephrine

Dopamine agonists

Fenoldopam

Both

Unknown/ungrouped

Phosphodiesterase inhibitors (PDE3I)

Other cardiac stimulants

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

v t e Vasodilators used incardiac diseases (C01D)
Nitrovasodilators	Nitroglycerin # Isosorbide dinitrate # Isosorbide mononitrate Itramin tosilate Linsidomine Molsidomine Nicorandil Pentaerythritol tetranitrate Propatylnitrate Tenitramine Trolnitrate
Quinolone vasodilators	Flosequinan^‡
Others	Benziodarone Carbocromen Cinepazet Cloridarol Dilazep Efloxate Etafenone Gapicomine Heptaminol Hexobendine Imolamine Levosimendan Nesiritide Nicorandil Oxyfedrine Pimobendan Prenylamine Serelaxin Trapidil Vericiguat
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III

Sympatholytic (and closely related)antihypertensives (C02)

Sympatholytics
(antagonizeα-adrenergic
vasoconstriction)

Central

α₂-Adrenergic receptor agonists	Clonidine Guanabenz Guanfacine Guanoxabenz Methyldopa^# Tiamenidine^‡
Adrenergic release inhibitors	Bethanidine Bretylium Debrisoquine Guanadrel Guanazodine Guancydine Guanethidine Guanoclor Guanoxan
Imidazoline receptor agonists	Moxonidine Rilmenidine Tolonidine
Ganglion-blocking/nicotinic antagonists	Hexamethonium^‡ Mecamylamine Pentolinium Trimethaphan

Peripheral

Indirect

Monoamine oxidase inhibitors	Pargyline^‡
VMAT inhibitors	Bietaserpine Deserpidine Methoserpidine Reserpine Syrosingopine
Tyrosine hydroxylase inhibitors	Metirosine

Direct

α₁-Adrenergic receptor blockers	Doxazosin Ketanserin Indoramin Prazosin Trimazosin Urapidil
Non-selective α-adrenergic receptor blockers	Phentolamine

Otherantagonists

Serotonin receptor antagonists	Ketanserin Lidanserin
Endothelin receptor antagonists (for PHTooltip Pulmonary hypertension)	dual (Aprocitentan,Bosentan,Macitentan (+tadalafil),Riociguat) selective (Ambrisentan (+tadalafil),Sitaxentan,Sotatercept)

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

v t e Nonsympatholyticvasodilatory antihypertensives (C02)
Nitrovasodilator (arterioles and venules)	Nitroprusside #
Hydrazinophthalazines (arterioles)	Hydralazine # Dihydralazine Endralazine Cadralazine Pildralazine
Potassium channel openers (arterioles)	Minoxidil Diazoxide
Calcium channel blockers (arterioles)	seelist
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III

Diuretics (C03)

Sulfonamides
(andetacrynic acid)

CA inhibitors (atPT)	Acetazolamide
Loop (Na-K-Cl atAL)	Furosemide^# Azosemide Bumetanide Etacrynic acid Etozolin Indacrinone Muzolimine Ozolinone Piretanide Tienilic acid^‡ Torasemide
Thiazides (Na-Cl atDCT, Calcium-sparing)	Altizide Bendroflumethiazide Butizide Chlorothiazide Cyclopenthiazide Cyclothiazide Epitizide Hydrochlorothiazide Hydroflumethiazide Mebutizide Methyclothiazide Polythiazide Trichlormethiazide
Thiazide-likes (primarilyDCT)	Chlortalidone Clofenamide Clopamide Clorexolone Fenquizone Indapamide (+telmisartan and amlodipine) Mefruside Meticrane Metolazone Quinethazone Xipamide

Potassium-sparing (atCD)

ESC blockers	Amiloride^# Benzamil Triamterene
Aldosterone antagonists	Spirolactones Spironolactone^# Canrenone Eplerenone Potassium canrenoate Nonsteroidal Finerenone

Osmotic diuretics (PT,DL)

Vasopressin receptor inhibitors
(DCT andCD)

Vaptans

Others
- Demeclocycline
- Lithium carbonate

Other

Combination products

Hydrochlorothiazide/triamterene

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

v t e Peripheral vasodilators (C04)
Phenylethanolamine derivatives	Isoxsuprine Buphenine Bamethan
Alpha blockers	Non-selective Buflomedil Phentolamine Phenoxybenzamine Tolazoline Selectiveα₁-blockers Alfuzosin Doxazosin Prazosin Silodosin Tamsulosin Terazosin
Nicotinic acid and derivatives	Nicotinic acid Nicotinyl alcohol Inositol nicotinate Ciclonicate
Purine derivatives	Pentifylline Xantinol nicotinate Pentoxifylline Etofylline nicotinate
Ergot alkaloids	Ergoloid Nicergoline Dihydroergocristine
Other peripheral vasodilators	Cyclandelate Vincamine Moxisylyte Bencyclane Vinburnine Sulcotidil Naftidrofuryl Butalamine Visnadine Cetiedil Cinepazide Ifenprodil Azapetine Fasudil

Vasoprotectives (C05)

Antihemorrhoidals for topical use

corticosteroids	Hydrocortisone Prednisolone Betamethasone Fluorometholone Fluocortolone Dexamethasone Fluocinolone acetonide Fluocinonide
local anesthetics	Lidocaine Tetracaine Benzocaine Dibucaine Procaine Oxetacaine Pramocaine
other	Tribenoside

Antivaricose therapy

heparins orheparinoids for topical use	Organo-heparinoid Sodium apolate Heparin Pentosan polysulfate
sclerosing agents for local injection	Monoethanolamine oleate Polidocanol Inverted sugar syrup Sodium tetradecyl sulfate Phenol
other	Calcium dobesilate

Capillary stabilising agents

bioflavonoids	Rutoside Monoxerutin Diosmin Troxerutin Hidrosmin
other	Tribenoside Etamsylate

v t e Beta blockers (C07)
β, non-selective	Alprenolol Bopindolol Bupranolol Carteolol Cloranolol Mepindolol Nadolol Oxprenolol Penbutolol Pindolol/Iodopindolol Propranolol^# Sotalol Tertatolol Timolol^#
β₁-selective	Acebutolol Atenolol Betaxolol Bevantolol Bisoprolol^# Celiprolol Epanolol Esmolol Landiolol Metoprolol Nebivolol Practolol Talinolol
β₂-selective	Butaxamine
α₁- + β-selective	Arotinolol Carvedilol Labetalol
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III

Ion channel modulators

Calcium

VDCCsTooltip Voltage-dependent calcium channels

Blockers

R-type-selective:SNX-482

Activators

L-type-selective:Bay K8644

Potassium

VGKCsTooltip Voltage-gated potassium channels

Blockers

Activators

KCNQ (K_v7)-specific:Flupirtine
Retigabine

IRKsTooltip Inwardly rectifying potassium channel

Blockers

K_ATPTooltip ATP-sensitive potassium channel-specific:Acetohexamide
Carbutamide
Chlorpropamide
Glibenclamide (glyburide)
Glibornuride
Glicaramide
Gliclazide
Glimepiride
Glipizide
Gliquidone
Glisoxepide
Glyclopyramide
Glycyclamide
Metahexamide
Mitiglinide
Nateglinide
Repaglinide
Tolazamide
Tolbutamide

GIRKTooltip G protein-coupled inwardly rectifying potassium channel-specific:Barium
Caramiphen
Cloperastine
Clozapine
Dextromethorphan
Ethosuximide
Ifenprodil
Tertiapin
Tipepidine

Activators

K_ATPTooltip ATP-sensitive potassium channel-specific:Aprikalim
Bimakalim
Cromakalim
Diazoxide
Emakalim
Levcromakalim
Mazokalim
Minoxidil
Minoxidil sulfate
Naminidil
Nicorandil
Pinacidil
Rilmakalim
Sarakalim

GIRKTooltip G protein-coupled inwardly rectifying potassium channel-specific:ML-297 (VU0456810)

K_CaTooltip Calcium-activated potassium channel

Blockers	BK_Ca-specific:Ethanol (alcohol) GAL-021
Activators	BK_Ca-specific:Flufenamic acid Meclofenamic acid Niflumic acid Nimesulide Rottlerin (mallotoxin) Tolfenamic acid

K2PsTooltip Tandem pore domain potassium channel

Blockers	12-O-Tetradecanoylphorbol-13-acetate Arachidonic acid Fluoxetine Norfluoxetine
Activators	Riluzole

Sodium

VGSCsTooltip Voltage-gated sodium channels

Blockers

Antianginals:Ranolazine

Activators

Aconitine
Atracotoxins (ω-Atracotoxin,Robustoxin,Versutoxin)
Batrachotoxin
Ciguatoxins
Grayanotoxins
Poneratoxin

ENaCTooltip Epithelial sodium channel

Blockers	Amiloride Benzamil Triamterene
Activators	Solnatide

ASICsTooltip Acid-sensing ion channel

Blockers	A-317567 Amiloride Aspirin Ibuprofen PcTX1

Chloride

CaCCsTooltip Calcium-activated chloride channel

Blockers	Crofelemer DIDS Ethacrynic acid Flufenamic acid Fluoxetine Furosemide Glibenclamide Mefloquine Mibefradil Niflumic acid
Activators	Carbachol

CFTRTooltip Cystic fibrosis transmembrane conductance regulator

Blockers	Glibenclamide Lonidamine Piretanide
Activators	1,7-Phenanthroline 1,10-Phenanthroline 4,7-Phenanthroline 7,8-Benzoquinoline Ivacaftor Phenanthridine

Unsorted

Blockers	Bumetanide Flufenamic acid Meclofenamic acid Mefenamic acid Mepacrine Niflumic acid Talniflumate Tolfenamic acid Trifluoperazine

Others

TRPsTooltip Transient receptor potential channels	Seehere instead.
LGICsTooltip Ligand gated ion channels	Seehere instead.

See also:Receptor/signaling modulators •Transient receptor potential channel modulators

v t e Antihypertensive drugs acting on therenin–angiotensin system (C09)
ACE inhibitors ("-pril")	Sulfhydryl-containing:Captopril Rentiapril Zofenopril (+nebivolol) Dicarboxylate-containing:Enalapril^# (+lercanidipine,+nitrendipine) Benazepril (+amlodipine,+pimobendan) Cilazapril Delapril (+manidipine) Imidapril Lisinopril (+amlodipine,+HCT) Moexipril Perindopril (+amlodipine,+bisoprolol,+indapamide,+amlodipine and indapamide,+bisoprolol and amlodipine,+bisoprolol, amlodipine, and indapamide) Quinapril (+HCT) Ramipril (+amlodipine,+amlodipine and HCT,+bisoprolol,+felodipine) Spirapril Temocapril Trandolapril (+verapamil) Phosphonate-containing:Ceronapril Fosinopril (+HCT) Other/ungrouped:Alacepril
AIIRAs ("-sartan")	Azilsartan Candesartan (+amlodipine,+amlodipine and HCT) Eprosartan Fimasartan Irbesartan (+amlodipine,+amlodipine and HCT,+HCT) Losartan (+amlodipine,+HCT) Olmesartan (+amlodipine,+amlodipine and HCT,+HCT) Tasosartan^§ Telmisartan (+amlodipine,+amlodipine and HCT,+amlodipine and indapamide,+HCT) Valsartan (+aliskiren,+amlodipine,+amlodipine and HCT,+HCT,+lercanidipine,+nebivolol,+sacubitril)
Renin inhibitors ("-kiren")	Aliskiren (+amlodipine,+HCT,+amlodipine and HCT) Remikiren^§
DualACE/NEP inhibitors	Gemopatrilat Ilepatril Omapatrilat Sampatrilat
Neprilysin inhibitors	Sacubitril (+valsartan)
Other	Sparsentan
^#WHO-EM ^‡Withdrawn from market Clinical trials: ^†Phase III ^§Never to phase III

Lipid-lowering agents (C10)

GI tract

Cholesterol absorption inhibitors,NPC1L1	Ezetimibe Hyzetimibe SCH-48461
Bile acid sequestrants/resins (LDL)	Colesevelam Colestilan Colestipol Colestyramine Colextran Soluble fiber such aspsyllium andglucomannan

Liver

Statins (HMG-CoA reductase,LDL)	Atorvastatin Cerivastatin^‡ Fluvastatin Lovastatin Mevastatin Pitavastatin Pravastatin Rosuvastatin Simvastatin^#
Niacin and derivatives (HDL andLDL)	Acipimox Aluminium nicotinate Nicotinic acid Niceritrol Nicofuranose Nicotinyl alcohol
MTTP inhibitors (VLDL)	Dirlotapide Lomitapide Mitratapide
ATP citrate lyase inhibitors (LDL)	Bempedoic acid
Thyromimetics (VLDL)	Dextrothyroxine^‡ Resmetirom

Blood vessels

PPAR agonists (LDL)

Fibrates	Aluminium clofibrate Bezafibrate Choline fenofibrate Ciprofibrate Clinofibrate Clofibrate^‡ Clofibride Etofibrate Fenofibrate Gemfibrozil Nafenopin Pemafibrate Ronifibrate Simfibrate
Others	GW501516^§

CETP inhibitors (HDL)

PCSK9 inhibitors (LDL)

ANGPTL3 inhibitors (LDL/HDL)

Evinacumab

Combinations

Other

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Retrieved from "https://en.wikipedia.org/w/index.php?title=ATC_code_C&oldid=1090055154"

Category:

ATC codes

Hidden categories:

[8]ページ先頭